Dror Harats, VBL Therapeutics CEO

Gene ther­a­py for ovar­i­an can­cer fails PhI­II study — sink­ing biotech's shares

De­spite promis­ing in­ter­im re­sults, VBL Ther­a­peu­tics’ ovar­i­an can­cer drug has ul­ti­mate­ly flopped in a Phase III tri­al.

The Nas­daq-list­ed Is­raeli biotech re­vealed that the OVAL tri­al of ofran­er­gene obade­n­ovec (al­so known as ofra-vec, or VB-111) did not meet the pri­ma­ry end­points of im­prov­ing up­on pro­gres­sion-free sur­vival or over­all sur­vival.

“Based on this out­come, we plan to dis­con­tin­ue the OVAL tri­al and will re­view the da­ta from our on­go­ing Phase 2 tri­als in metasta­t­ic col­orec­tal can­cer and re­cur­rent glioblas­toma mul­ti­forme to de­ter­mine next steps with the ofra-vec pro­gram,” CEO Dror Harats said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.